Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Klangjareonchai, Theerawut ^a   Nimitphong, Hataikarn ^a   Saetung, Sunee ^a   Bhirommuang, Nuttapimon ^a   Samittarucksa, Rattanapan ^a   Chanprasertyothin, Suwannee ^a   Sudatip, Rattana ^a   Ongphiphadhanakul, Boonsong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; HEMOGLOBIN A1C; IRISIN; SCLEROSTIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SEX DIFFERENCE;

EID: 84929481202     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/261545     Document Type: Article

References (28)

1. C. Y. Logan and R. Nusse, "The Wnt signaling pathway in development and disease", Annual Review of Cell and Developmental Biology, vol. 20, pp. 781-810, 2004.
2. C. Christodoulides, C. Lagathu, J. K. Sethi, and A. Vidal-Puig, "Adipogenesis and WNT signalling", Trends in Endocrinology and Metabolism, vol. 20, no. 1, pp. 16-24, 2009.
3. M. J. Moester, S. E. Papapoulos, C. W. Löwik, and R. L. van Bezooijen, "Sclerostin: current knowledge and future perspectives", Calcified Tissue International, vol. 87, no. 2, pp. 99-107, 2010.
4. T. Urano, M. Shiraki, Y. Ouchi, and S. Inoue, "Association of circulating sclerostin levels with fat mass and metabolic disease-relatedmarkers in Japanese postmenopausal women", Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 8, pp. E1473-E1477, 2012.
5. Z. Sheng, D. Tong, Y. Ou et al., "Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women", Clinical Endocrinology, vol. 76, no. 6, pp. 797-801, 2012.
6. L. Gennari, D. Merlotti, R. Valenti et al., "Circulating Sclerostin levels andbone turnover in type 1 and type2diabetes", Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 5, pp. 1737-1744, 2012.
7. M.-S. M. Ardawi, D. H. Akhbar, A. AlShaikh et al., "Increased serumsclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes", Bone, vol. 56, no. 2, pp. 355-362, 2013.
8. A. García-Martín, P. Rozas-Moreno, R. Reyes-García et al., "Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus", The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 1, pp. 234-241, 2012.
9. A. H. van Lierop, J. E. Witteveen, N. A. T. Hamdy, and S. E. Papapoulos, "Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls", European Journal of Endocrinology, vol. 163, no. 5, pp. 833-837, 2010.
10. A. Gaudio, P. Pennisi, C. Bratengeier et al., "Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2248-2253, 2010.
11. M.-S. M. Ardawi, H. A. Al-Kadi, A. A. Rouzi, and M. H. Qari, "Determinants of serum sclerostin in healthy pre- and postmenopausal women", Journal of Bone and Mineral Research, vol. 26, no. 12, pp. 2812-2822, 2011.
12. U. I. Mödder, K. A. Hoey, S. Amin et al., "Relation of age, gender, and bone mass to circulating sclerostin levels in women and men", Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 373-379, 2011.
13. P. Boström, J. Wu, M. P. Jedrychowski et al., "A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis", Nature, vol. 481, no. 7382, pp. 463-468, 2012.
14. B. M. Spiegelman, "Banting lecture 2012: regulation of adipogenesis: toward new therapeutics for metabolic disease", Diabetes, vol. 62, no. 6, pp. 1774-1782, 2013.
15. M. G. Novelle, C. Contreras, A. Romero-Picó, M. López, and C. Diéguez, "Irisin, two years later", International Journal of Endocrinology, vol. 2013, Article ID 746281, 8 pages, 2013.
16. J. M. Moreno-Navarrete, F. Ortega, M. Serrano et al., "Irisin is expressed and produced by humanmuscle and adipose tissue in association with obesity and insulin resistance", The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. E769-E778, 2013.
17. J. Y. Huh, G. Panagiotou, V. Mougios et al., "FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise", Metabolism: Clinical and Experimental, vol. 61, no. 12, pp. 1725-1738, 2012.
18. A. B. Crujeiras, M. Pardo, R. R. Arturo et al., "Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women", American Journal of Human Biology, vol. 26, no. 2, pp. 198-207, 2014.
19. American Diabetes Association, "Standards of medical care in diabetes-2013", Diabetes Care, vol. 36, supplement 1, pp. S11-S66, 2013.
20. E. Schoenau, "From mechanostat theory to development of the "functional muscle-bone-unit"", Journal of Musculoskeletal Neuronal Interactions, vol. 5, no. 3, pp. 232-238, 2005.
21. S. Rahman, Y. Lu, P. J. Czernik, C. J. Rosen, S. Enerback, and B. Lecka-Czernik, "Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton", Endocrinology, vol. 154, no. 8, pp. 2687-2701, 2013.
22. K. Amrein, S. Amrein, C. Drexler et al., "Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults", Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 148-154, 2012.
23. J. C. K. Wells, "Sexual dimorphism of body composition", Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 21, no. 3, pp. 415-430, 2007.
24. S. R. Davis, K. Z. Walker, and B. J. Strauss, "Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women", Menopause, vol. 7, no. 6, pp. 395-401, 2000.
25. F. S. Mirza, I. D. Padhi, L. G. Raisz, and J. A. Lorenzo, "Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 4, pp. 1991-1997, 2010.
26. U. I. Mödder, J. A. Clowes, K. Hoey et al., "Regulation of circulating sclerostin levels by sex steroids in women and in men", Journal of Bone and Mineral Research, vol. 26, no. 1, pp. 27-34, 2011.
27. N. M. Al-Daghri, K. M. Alkharfy, S. Rahman et al., "Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects", European Journal of Clinical Investigation, vol. 44, no. 2, pp. 119-124, 2014.
28. M. T. Drake, B. Srinivasan, U. I. Mödder et al., "Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 11, pp. 5056-5062, 2010.